Get the Stockscreener App
41.54
1.68%
-0.71
After Hours:
41.50
-0.04
-0.10%
Enliven Therapeutics Inc stock is traded at $41.54, with a volume of 631.94K.
It is down -1.68% in the last 24 hours and down -6.53% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$42.25
Open:
$42.81
24h Volume:
631.94K
Relative Volume:
0.59
Market Cap:
$2.53B
Revenue:
-
Net Income/Loss:
$-103.69M
P/E Ratio:
-22.36
EPS:
-1.8579
Net Cash Flow:
$-70.46M
1W Performance:
+0.48%
1M Performance:
-6.53%
6M Performance:
+90.99%
1Y Performance:
+147.70%
1-Day Range:
$41.43
$43.05
1-Week Range:
$38.58
$43.05
52-Week Range:
$14.79
$48.53
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
41.54 | 2.57B | 0 | -103.69M | -70.46M | -1.8579 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
The Technical Signals Behind (ELVN) That Institutions Follow - Stock Traders Daily
Biopharma Enliven joins TD Cowen, Jefferies investor chats online - Stock Titan
Enliven Therapeutics to Present at Upcoming Investor Conferences - Moomoo
Enliven Therapeutics CMO sells $198,971 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CMO sells $198,971 in stock - Investing.com
Enliven Therapeutics (ELVN) CMO trades 5,000 shares and exercises 5,000 options - Stock Titan
Enliven Therapeutics (NASDAQ: ELVN) proposed 15,000-share sale via Jefferies - Stock Titan
Polar Capital (ELVN) discloses 5.06M shares; 8.46% ownership reported - Stock Titan
Vestal Point / Ryan Wilder report 3.25M shares in Enliven Therapeutics (ELVN) - Stock Titan
Venrock group discloses 1.73M ELVN shares (2.8% of float) - Stock Titan
Fairmount files 13G/A: 1.86M shares (3.1%) in Enliven Therapeutics (ELVN) - Stock Titan
Commodore holds 4.8M shares in Enliven (NASDAQ: ELVN) after amendment - Stock Titan
Polar Capital (ELVN) discloses 5.07M shares, 8.47% stake in ENLIVEN - Stock Titan
JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Enliven Therapeutics (ELVN) Slips -3.15%, Testing $40.08 Support 2026-05-14Hot Stocks - newser.com
ELVN stock climbs as Guggenheim launches coverage with $80 price target ahead of conference data unveil - MSN
Precision Trading with Enliven Therapeutics Inc. (ELVN) Risk Zones - Stock Traders Daily
ELVN Stock Climbs As Guggenheim Launches Coverage With $80 Price Target Ahead Of Conference Data Unveil - Stocktwits
Enliven to present updated ELVN-001 leukemia trial data at EHA By Investing.com - Investing.com South Africa
Enliven to present updated ELVN-001 leukemia trial data at EHA - Investing.com Australia
Enliven Therapeutics Insiders Sell US$644k Of Stock, Possibly Signalling Caution - Moomoo
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML - PR Newswire
Guggenheim Initiates Coverage on Enliven Therapeutics With Buy, $80 Price Target - marketscreener.com
A Look At Enliven Therapeutics (ELVN) Valuation After Analyst Support And Phase 3 Trial Plans - Sahm
TradingKey - TradingKey
Guggenheim initiates Enliven Therapeutics stock with buy rating By Investing.com - Investing.com Canada
Guggenheim Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $80 - Moomoo
Merck & Co. Inc. (MRK)Strategic Investment Implications from Clinical-Stage Oncology Pipeline DevelopmentsCompetitive Risk - newser.com
Why is Enliven Therapeutics (ELVN) One of the Best Performing Healthcare Stocks so Far in 2026? - Insider Monkey
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development - Quantisnow
Enliven: Drug candidate ‘has the potential to be the best-in-class’ - BizWest
5 Best Performing Healthcare Stocks So Far in 2026 - Insider Monkey
Goldman Sachs Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $59 - Moomoo
Enliven Therapeutics, Inc. (ELVN) - DirectorsTalk Interviews
JonesTrading Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $45 - Moomoo
Enliven Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Q1 2026: Enliven Therapeutics (NASDAQ: ELVN) narrows loss, holds $452M cash - Stock Titan
Enliven Therapeutics Q1 net loss narrows as R&D spending reduces - TradingView
Enliven Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Enliven Therapeutics (NASDAQ: ELVN) narrows loss and targets Phase 3 trial - Stock Titan
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update - marketscreener.com
Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio - MSN
Enliven Therapeutics (ELVN) price target increased by 11.14% to 52.02 - MSN
Wall Street Zen Downgrades Enliven Therapeutics (NASDAQ:ELVN) to Sell - MarketBeat
Pictet Asset Management Holding SA Sells 94,852 Shares of Enliven Therapeutics, Inc. $ELVN - MarketBeat
Director sale notice — Enliven Therapeutics (NASDAQ: ELVN) files Form 144 - Stock Titan
[ARS] Enliven Therapeutics, Inc. SEC Filing - Stock Titan
Enliven Therapeutics (NASDAQ: ELVN) seeks larger share authorization - Stock Titan
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Enliven Therapeutics Inc Stock (ELVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Collins Helen Louise | CHIEF MEDICAL OFFICER |
May 18 '26 |
Sale |
39.79 |
5,000 |
198,971 |
25,000 |
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):